Status:
TERMINATED
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Body weight \>/=99 lbs
- ECOG 0-2
- Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
- Screening hemoglobin level of \</=11.0 g/dL for men or \</=10.0 for women
Exclusion
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00083486
Start Date
February 1 2004
End Date
October 1 2004
Last Update
April 27 2011
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Heritage Physician Group-Oncology
Hot Springs, Arkansas, United States, 71913
2
Spalding Oncology Services
Griffin, Georgia, United States, 30224
3
Southern Illinois Hematology
Centralia, Illinois, United States, 62801
4
BioLab Research
Rockville, Maryland, United States, 20852